Privacy Policy

Apertura Gene Therapy (“Apertura”, “we”, “us”, “our”) is committed to protecting the privacy of its online visitors. This Privacy Policy is designed to explain our online information practices in connection with this website provided by Apertura (the “Website”). Apertura does not collect information about you other than as described below. By using this Website, you are agreeing to this Privacy Policy.

Please review the following to understand how we process personal data about you. By using this Website, including by voluntarily providing personal data to us, you acknowledge that you have read and understand the practices contained in this Privacy Policy. This Privacy Policy may be revised from time to time, so please ensure that you check this Privacy Policy periodically to remain fully informed.

We collect personal data from and about you through your usage of this Website, including:

  • When you provide it to us directly;
  • Automatically through logging and analytics tools, cookies, pixel tags, and as a result of your use of and access to the Services; and
  • From third-party sources, including service providers such as Google Analytics.
  • Finally, we may collect data that is not identifiable to you or otherwise associated with you, such as aggregated data, that is not personal data. To the extent this data is stored or associated with personal data, it will be treated as personal data; otherwise, the data is not subject to this Privacy Policy.

Apertura does not require you to register or provide information to us in order to view our Website. Apertura gathers personal information (“PI”), such as names, addresses, zip/postal codes, e-mail addresses, when voluntarily submitted by a visitor. For example, PI may be collected from you in connection with you applying for a job with us, or by contacting us with questions or comments.

Some areas of our Website may require some identification as a part of participation. In each case, we will make it clear what PI will be collected and how we will use it.

Apertura may utilize advertising networks and third-party analytics services that automatically collect and temporarily store certain information about your visit to our Website, including (i) the pages of our Website that you visited; (ii) the time and date of your visit; and (iii) the address of the website that you came from when you entered our Website. This information would be aggregated and anonymized, and we use it to help diagnose problems with our server and to improve our Website’s content.

We may also utilize – directly or indirectly through a third-party service provider – technical methods in HTML emails that we may send to determine whether you have opened those emails or clicked on links in the emails.

Although some web browsers offer “do not track” options, the Website does not currently honor “do-not-track” browser settings.

Cookies are small pieces of information that are stored by your browser on your computer’s hard drive. We use cookies to enhance your experience on our Website. Cookies may collect such information as your IP address to identify the device that you use. Users may have the opportunity to set their computers to accept all cookies, to notify them when a cookie is issued or not to receive cookies at any time. If you set your browser not to accept cookies, you may not be able to take advantage of the full features of the Website.

Apertura is the sole owner of any information collected on this Website. We will not share your information with any third-party organization for commercial purposes except as noted in this policy.

Apertura may share your information, including PI, with affiliated and non-affiliated third parties as follows:

  • As necessary to provide you with information or materials you request;
  • To respond to a subpoena or court order, judicial process or regulatory inquiry;
  • When required by applicable law, including laws outside your country of residence;
  • To protect or defend against fraud, lawsuits, claims or other liabilities;
  • To protect the security of our systems, or to protect our rights or property;
  • In connection with a proposed or actual sale, merger, or transfer of all or a portion of Apertura’s business;
  • To otherwise assist Apertura in offering products and services;
  • To social media platforms in order to provide you with information about Apertura’s activities;
  • To service providers, including software and Web developers, commercial email providers, security consultants, and other vendors we engage so that they may provide services to us or on our behalf; and
  • With certain affiliates, partners, prospective partners, and service providers in order to provide us and/or our affiliates and partners with information about the use of the Website, our products and services and levels of engagement with the Website, our products and services and to allow us to enter into new business relationships and in connection with recruiting activities.

In each of these instances, Apertura has no obligation to notify you of such disclosures, except as required by applicable law.

The PI you provide may also be available to third-party application service providers that we have engaged to operate this Website.

California Civil Code Section 1798.83, known as the “Shine the Light” law, permits our users who are California residents to request and obtain from us a list of what personal data (if any) we disclosed to third parties for their own direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Requests may be made only once per year per person, must be sent to the email address below, and are free of charge.

We do not disclose personal data protected under the “Shine the Light” law to third parties for their own direct marketing purposes.

Apertura is headquartered in the US and any information that we collect will be transferred to our servers in the US. If you use our services or access our Website from another country, you expressly agree to the transfer of your information to the US. To the extent you have questions or concerns with regard to your rights regarding our collection and processing of personal information in your country, please contact us at the email address provided below.

Apertura takes steps intended to secure the PI provided to us. For example, PI you provide is accessible only by designated personnel.

We employ reasonable physical, technical and organizational safeguards to promote the security of our systems and protect the confidentiality, integrity, availability and resilience of your PI. Please note, however, that no data transmission over the Internet can be guaranteed to be totally secure. While we use these measures to protect your PI, we cannot guarantee that our safeguards will be effective or sufficient. Additionally, please be aware that since Internet data submissions are not always secure, we cannot warrant that information you transmit utilizing the Website is or will be secure.

We generally retain PI for as long as reasonably needed for the specific business purpose or purposes for which it was collected and the duration of your use of our Website(s), apps and other relevant online tools.

If you supply us with your postal address or e-mail address online, you may receive periodic communications from us with information on our programs and services. If you do not want to receive postal mail and/or e-mail from us in the future, please let us know by sending your request via the unsubscribe link contained in our e-mails or by contacting us as set out below.

Apertura will never rent, trade or sell your e-mail address. However, we may occasionally share your name and postal address with our service providers.

The accuracy of your PI is important to Apertura. If you would like to review or delete any PI you have provided to us, please contact us at the email address below, and we will consider your request. We reserve the right to deny to any such request if we deem it to not be commercially reasonable or otherwise injurious or inappropriate, except to the extent fulfilling the request is required by applicable law.

In order to provide certain services and materials, our Website may allow you to “click” over to other websites. This Privacy Policy only applies to the Website and does not apply to any third-party sites. Apertura is not responsible for the privacy practices or content of such other third-party sites, even if our name and logo appear on such websites. We recommend that you review the privacy policies on third-party sites before you use any services or programs they offer.

Apertura does not knowingly solicit or collect PI from anyone under the age of 13. Visitors under the age of 13 should ask their parent or legal guardian for assistance when using this Website and should not submit any PI to Apertura. In the event we learn that we have collected PI from a child under age 13, we will delete that information.

In the event another organization merges with or acquires Apertura or substantially all of its assets, your PI may be transferred to that successor or acquiring entity. A court also may order the sale of PI as an asset in a bankruptcy or similar insolvency proceeding.

This Privacy Policy replaces all previous disclosures we may have provided to you about our information practices with respect to the Website. We reserve the right, at any time, to modify, alter, and/or update this Privacy Policy without advance notice, and any such modifications, alterations, or updates will be effective upon our posting of the revised Privacy Policy. Your continued use of the Website following our posting of any revised Privacy Policy will constitute your acknowledgement of the amended Privacy Policy.

This Privacy Policy is subject to any agreements, including the Terms of Use that govern your use of the Website. This Privacy Policy applies regardless of the means used to access or provide information through the Website.

This Privacy Policy, however, does not apply to information from or about you collected by any third-party services, applications, or advertisements associated with, or websites linked from, the Website. The collection or receipt of your information by such third parties is subject to their own privacy policies, statements, and practices, and under no circumstances are we responsible or liable for any third party’s compliance therewith.

For Additional Information
If you have any questions about this Privacy Policy, including how we process PI, please contact us at:

345 Park Avenue South
New York, NY 10010

In order to make this Privacy Notice reasonably accessible to users with disabilities, we follow the Web Content Accessibility Guidelines (WCAG 2.1). Users with disabilities may access the Website, including this Privacy Policy, using standing navigation on the website through the aid of additional software, such as screen readers.

Scroll to Top

Natalie McAndrew

Vice President of Finance

Natalie McAndrew is Vice President of Finance at Apertura Gene Therapy and is an accomplished director of finance and accounting functions with over 18 years of experience serving early stage, high-growth, and publically traded companies in life sciences and biotechnology. Prior to joining Apertura, she was a director level consultant with Danforth Financial Advisors supporting all stages of life science companies from Pre-IPO to public traded companies with commercial products. In her role she supported ArriVent Biopharma in their recent IPO and was instrumental in helping to improve financial efficiency for Esperion Therapeutics, Excision Biopharma, and Tmunity Therapeutics. Prior to joining Danforth, she was Head of Finance at Spark Therapeutics and for over 6 years managed the growth of the finance department overseeing public company compliance and helping to raise more than $1 billion in capital from private and public financing and accounting for the first gene therapy commercial product on the market.  Prior to Spark, she held Controller roles at Renmatix and Tengion. Mrs. McAndrew earned a BS in Accounting from King’s College and is a licensed CPA.

Juliana Leung, PhD

The Broad Institute

Juliana Leung, PhD, is the Senior Director of Business Development and Licensing Transactions at the Broad Institute of MIT and Harvard, where she leads Broad’s business development and licensing team. She has more than 15 years of business development and transactional experience. Juliana provides expertise to build collaborations with industry as well as partnerships with pharma, biotech, and venture groups that are eager to translate technologies into products that can benefit patients, the research community, and improve human health.

Before joining the Broad in 2012, Juliana was Senior Business Strategy and Licensing Manager for Research Ventures and Licensing at Partners Healthcare, now referred to as Innovation at MassGeneral Brigham. She received her SB in Biology from MIT and her PhD in Cellular, Molecular and Biophysical Studies from Columbia University in New York.

Ben Deverman, PhD

Senior Director of Vector Engineering at the Broad Institute of MIT and Harvard

Ben Deverman is the Senior Director of Vector Engineering and an Institute Scientist at the Broad Institute of MIT and Harvard. Ben’s laboratory in the Stanley Center for Psychiatric Research at the Broad Institute develops and applies novel high-throughput screens and data-driven protein and genome engineering techniques to create more efficient and targeted AAV vectors to advance gene therapy and support scientific discovery. In prior work at the California Institute of Technology, Ben and colleagues identified numerous capsids, including AAV-PHP.B and an enhanced variant, AAV-PHP.eB, that made efficient brain-wide gene delivery possible for the first time. Ben earned a PhD in Molecular Cell Biology from Washington University and was trained as a postdoc in neuroscience at the California Institute of Technology.

Michael Greenberg, PhD

Chair of the Department of Neurobiology and the Nathan Marsh Pusey Professor of Neurobiology at Harvard Medical School

Dr. Greenberg received his PhD from The Rockefeller University in 1982 and carried out his postdoctoral research at New York University Medical Center. After joining the faculty at Harvard Medical School in 1986, Dr. Greenberg served first as the founding Director of the F.M. Kirby Neurobiology Center at Boston Children’s Hospital and since 2008 as Chair of the Department of Neurobiology at Harvard Medical School.

Joseph La Barge

Apertura Gene Therapy

Joseph La Barge is CEO and serves on the Board of Managers of Apertura Gene Therapy. Previously, Mr. La Barge was an executive at Spark Therapeutics, Inc., serving as Chief Business Officer from 2019 to 2021 and as Chief Legal Officer from 2013 to 2019. In these roles, he oversaw many areas of company growth, including business development, patient advocacy, quality assurance, legal affairs, compliance, finance, public policy and global pricing and reimbursement, growing the company to 830 employees over eight years. He led the negotiation of Spark’s acquisition by Roche, raised more than $1 billion in capital from private and public financings and oversaw the in-license of numerous product candidates and platform technologies. Mr. La Barge also managed the acquisition and construction of Spark’s initial 180,000 square feet office and laboratory space, including GMP suites, to manufacture the global supply of Luxturna. Prior to Spark, Mr. La Barge served as Vice President, General Counsel & Secretary, Chief Compliance Officer at Tengion, Inc., where he was responsible for managing legal affairs, compliance and quality assurance. Mr. La Barge has served as a Member of the American Society of Gene & Cell Therapy Government Affairs Committee. He earned his BA in Education and Psychology at Bucknell University and his JD at Temple University James E. Beasley School of Law.

David Greenwald, PhD

Deerfield Management Company

Dave serves on the Board of Managers of Apertura Gene Therapy.

Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a BS in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his PhD in Genetics from Tufts University. Dr. Greenwald currently serves on the Boards of Jaguar Gene Therapy, Axovia Therapeutics, and Apertura Gene Therapy, and has worked at Deerfield Management since 2018.

Elise Wang

Deerfield Management Company

Ms. Wang is a Partner and Head of Private Equity Capital Markets on the Public Structured Finance team at Deerfield Management and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe.

Ms. Wang is a board member of Jaguar Gene Therapy. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director covering the biotechnology sector at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies.

Ms. Wang holds an AB in Engineering Sciences with a specialty in Biomechanics from Harvard University and an MBA from Harvard Business School.

Jonathan Leff

Deerfield Management Company

Mr. Leff is a Partner on the Therapeutics team at Deerfield Management since 2013 and Chairman of the Deerfield Institute. He focuses on venture capital and structured investments in biotechnology and pharmaceuticals. Prior to Deerfield, for more than sixteen years, Mr. Leff was with Warburg Pincus, where he led the firm’s investment efforts in biotechnology and pharmaceuticals. He is a member of the Boards of several private healthcare companies as well as several not-for-profit Boards, including the Spinal Muscular Atrophy Foundation, Friends of Cancer Research, Reagan-Udall Foundation for the Food and Drug Administration and the Columbia University Medical Center Board of Advisors. Mr. Leff has also been active in public policy discussions related to healthcare and medical innovation. He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), where he led NVCA’s life sciences industry efforts as Chair of NVCA’s Medical Innovation and Competitiveness Coalition (NVCA-MedIC), and also previously served on the Board of the Biotechnology Innovation Organization. Mr. Leff holds an AB from Harvard University and an MBA from Stanford University’s Graduate School of Business.

Roberto Pastrano

Vice President of Finance and Operations

Roberto Pastrano is Vice President of Finance and Operations at Apertura Gene Therapy. With over 17 years of Biotechnology and Pharmaceutical experience in finance, accounting, and operations, Mr. Pastrano oversees Apertura’s operations, IT, finance and accounting functions. Previously, Mr. Pastrano served as Senior Director and Corporate Controller at Day One Biopharmaceuticals, a biotechnology company focused on pediatric cancers, where he led the accounting, procurement, and IT functions. Prior to Day One, he spent six years at Loxo Oncology at Lilly, formerly Loxo Oncology, as Senior Director of Finance where he led the accounting, finance, procurement, and legal functions after joining the company as an Assistant Controller in August 2015. Notably, while at Loxo Oncology at Lilly, Mr. Pastrano played a key role in the development of Vitrakvi (larotrectinib), the second tissue agnostic FDA-approved drug for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion & Retevmo (selpercatinib), the first FDA-approved therapy for patients with lung and thyroid cancers with RET gene alterations, which was approved under the FDA’s Accelerated Approval pathway with an orphan drug designation. Mr. Pastrano holds a BS in Accounting from the City University of New York – Herbert H. Lehman College and an MBA with a concentration in Finance.

Andrew Steinsapir

Acting Chief Technology Officer

Andrew Steinsapir is the Acting Chief Technology Officer of Apertura Gene Therapy and a Director, Gene Therapy Program Lead of Deerfield Management’s Discovery and Development team. Prior to joining Deerfield in 2021, Mr. Steinsapir was a Consultant for over three years at Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms. Previous to Dark Horse, Mr. Steinsapir worked at 4D Molecular Therapeutics for over three years, holding various positions, with his most recent role being Senior Process Development Associate I. Mr. Steinsapir holds a BS in Chemical Engineering with an emphasis on Biotechnology from the University of California, Berkeley.

Jenna Heyman

Head of Human Resources, Vice President

Jenna Heyman joined Apertura Gene Therapy as Vice President and Head of Human Resources, bringing more than a decade of experience in Human Resources, as well as exceptional knowledge of building strong high performing teams in the biotechnology and CDMO industry. In her previous role as Vice President of Human Resources at Recipharm, Ms. Heyman oversaw HR for Arranta Bio and Vibalogics, and was instrumental in helping execute a global growth strategy. There, she was responsible for all operational and strategic activity in HR, including the areas of talent acquisition and retention, benefits and compensation, employee development and growth and corporate culture. Prior, Ms. Heyman served in progressive leadership positions at Brammer Bio, which was acquired by Thermo Fisher Scientific. Ms. Heyman has a BA in Psychology and an MA in Education from Quinnipiac University. She also holds a SHRM-SCP (Society of HR Management – Senior Certified Professional) certification.

Diego Garzón, PhD

Vice President of Corporate Development

Dr. Diego Garzón is Vice President of Corporate Development at Apertura Gene Therapy and has more than 16 years of biotechnology and pharmaceutical sector experience within the U.S. and internationally, with a background spanning commercial R&D and Business Development. Dr. Garzón brings extensive knowledge of multiple therapeutic areas and provides leadership in the areas of managing teams and portfolio execution, having previously brought seven medicines to the market. Prior to joining Apertura, Dr. Garzón held roles at Exicure, Allergan, BMS and Schering-Plough. He most recently served as Vice President, Corporate Development and Strategy at Exicure. Dr. Garzón received his BSc in Biology at the University of Waterloo, PhD in Neuroscience at McMaster University and MBA degrees from Queen’s University and Cornell University.

Sisi Chen, PhD

Senior Director of Platform Technology

Dr. Sisi Chen is  Senior Director of Platform Technology at Apertura Gene Therapy, where she and her teams are harnessing the power of machine learning and high-throughput experimentation to engineer better payloads and capsids for gene therapies. She brings over 15 years of research experience in technology development in the areas of functional and single-cell genomics, computational biology, and stem cell biology.Prior to Apertura, she served as the Director of the Beckman Single-cell Profiling and Engineering Center (SPEC) at Caltech, where she led a cross-functional computational and experimental team to leverage the power of single-cell genomics towards applications in therapeutic screening and cell engineering. Her work at SPEC on performing large-scale analyses of immune cell responses to small molecule drugs was awarded the Society of Laboratory Automation and Sciences (SLAS) 2021 Innovation Award. Dr. Chen earned a B.S. in Electrical engineering from MIT and a Ph.D. in Bioengineering from the University of California Berkeley.

Jorge Santiago-Ortiz, PhD

Senior Director of Chemistry, Manufacturing, and Controls (CMC)

Dr. Jorge Santiago-Ortiz is the Senior Director of Chemistry, Manufacturing, and Controls (CMC) at Apertura Gene Therapy. He is a chemical engineer with a background in bioprocess engineering, molecular biology, and biochemistry and a focus in gene therapy and process development. Born and raised in Puerto Rico, Jorge completed his bachelor’s degree in Chemical Engineering with a Biotechnology Certificate in 2010 at the University of Puerto Rico, Mayagüez; as an undergraduate student, he conducted research in biochemistry under Dr. Belinda Pastrana-Rios, where he worked on protein expression, purification, and characterization. In 2016, Jorge completed a Ph.D. in Chemical and Biomolecular Engineering with a minor in Molecular and Cell Biology at the University of California, Berkeley. Working in Dr. David Schaffer’s laboratory, his Ph.D. dissertation work focused on the engineering of lentiviral and adeno-associated virus (AAV) vectors for gene therapy applications using in vitro and in vivo directed evolution. Following the completion of his Ph.D., Jorge transitioned to an industry role at BioConsortia Inc. (Davis, CA), where he led the fermentation and scale-up of beneficial plant-associated microbes for enhanced crop yields and improved plant health. Prior to his current role at Apertura, Jorge worked as the Sr. Director of Process Development at BioCentriq, a gene and cell therapy contract development and manufacturing organization (CDMO) based in Newark, NJ, where he oversaw process development for gene and cell therapy clinical products and managed gene therapy projects. Jorge is an active member of the Society for Advancement of Chicanos/Hispanics & Native Americans in Science (SACNAS), and he also serves on the National Academies for Sciences, Engineering, and Medicine’s Standing Committee on Biotechnology Capabilities and National Security Needs and in the American Society of Gene and Cell Therapy’s Diversity, Equity, and Inclusion (DEI) Committee.

Apertura Benefits
Flexible Time Off
Medical, Dental, Vision
And more!

David Tischler

Strategy & Operations Consultant

David Tischler is an Advisor to Apertura Gene Therapy leveraging a background focused on building and financing companies to commercialize life science innovations. Currently, he is engaged by venture capital firms and their therapeutics and bioengineering-focused portfolio companies to lead operations, business development, fundraising, and strategic commercialization projects. Most recently, David was the co-founder and CEO of ZetaGen Therapeutics, an early-stage life science company developing targeted local therapies for large unmet needs in the regenerative medicine and oncology markets. Prior to ZetaGen, David was a product manager at Castlight Health (NYSE: CSLT), where he helped launch Action, an artificial intelligence product that uses machine learning to manage the health of employee populations of Fortune 100 companies. David also served as acting CEO of DigiSight Technologies (now Verana Health), a venture-backed company that leverages large datasets to manage retinal diseases. Previously, served as the due diligence chair for Mass Medical Angels, a life science-focused angel investment group and also worked as an associate at Venzyme Venture Catalyst where he turned early-stage life science technologies from academic institutions into financeable companies. David has a BS in Biology from the University of Michigan and an MBA from the UC Berkeley-Haas School of Business.

Jordan Dubow, MD

Acting Chief Medical Officer

Dr. Jordan Dubow is the Acting Chief Medical Officer of Apertura Gene Therapy. Dr Dubow is a neurologist with fellowship training in movement disorders and vascular neurology and began his medial career in academia as a movement disorders and stroke neurologist. Dr. Dubow has extensive experience in the pharmaceutical and biotech industry, where he has served in full time and acting CMO capacities for both pubic and private companies, leading all clinical and regulatory aspects of development for small and large molecule drugs and cell and gene therapies. Dr. Dubow received his medical degree from the Northwestern University Feinberg School of Medicine. He completed his internal medicine internship, Neurology residency and fellowship training at University of California Los Angeles, Northwestern University and Weill Cornell Medical College.

Joseph La Barge

Chief Executive Officer

Joseph La Barge is CEO and serves on the Board of Managers of Apertura Gene Therapy. Previously, Mr. La Barge was an executive at Spark Therapeutics, Inc., serving as Chief Business Officer from 2019 to 2021 and as Chief Legal Officer from 2013 to 2019. In these roles, he oversaw many areas of company growth, including business development, patient advocacy, quality assurance, legal affairs, compliance, finance, public policy and global pricing and reimbursement, growing the company to 830 employees over eight years. He led the negotiation of Spark’s acquisition by Roche, raised more than $1 billion in capital from private and public financings and oversaw the in-license of numerous product candidates and platform technologies. Mr. La Barge also managed the acquisition and construction of Spark’s initial 180,000 square feet office and laboratory space, including GMP suites, to manufacture the global supply of Luxturna. Prior to Spark, Mr. La Barge served as Vice President, General Counsel & Secretary, Chief Compliance Officer at Tengion, Inc., where he was responsible for managing legal affairs, compliance and quality assurance. Mr. La Barge has served as a Member of the American Society of Gene & Cell Therapy Government Affairs Committee. He earned his BA in Education and Psychology at Bucknell University and his JD at Temple University James E. Beasley School of Law.